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September 8, 2009:1036–40n a coronary segment already housing a double stent layer.
lthough dilation, with high-pressure noncompliant balloons, has
een advocated in patients with underexpanded stents, the results
f this strategy remains unsettled. Special care is required to
revent balloon slippage during these aggressive dilations. Alter-
ative techniques to overcome resistant areas of stent underexpan-
ion have not been systematically evaluated. Cutting balloon
ngioplasty and buddy-wire techniques have been proposed to
odify local wall stress, but again, their real value to tackle severe
tent underexpansion remains undefined (5). Finally, rotational
therectomy has been proposed in this setting, but the risks
ssociated with this highly aggressive approach seem rarely justi-
ed. In patients with ISR and unexpandable stents, the use of
dditional stenting should not be routinely advocated. However,
onsidering that in this scenario minor neointimal growth could
rigger recurrences, DES implantation, coupled with aggressive
ttempts to expand the underlying stents, seems reasonable. In
onclusion, in patients with recurrences after stenting for ISR,
ES implantation provides satisfactory long-term clinical, angio-
raphic, and IVUS results.
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revalence rate in sub-Saharan Africa will increase by 134% in men
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intravascular ultrasound.Letters to the Editoreveloping Sustainable
ardiovascular Care for
ow-Resource Nations
e read with keen interest the commentary by Weaver (1)
utlining the new international strategy of the American College
f Cardiology (ACC). We note, however, the failure of this new
trategic vision to address the greater need for developing sustain-
ble local infrastructure in emerging economies.
According to the World Health Organization (WHO), cardio-
ascular disease (CVD) is responsible for 17 million deaths
nnually, accounting for one-third of all global deaths, with nearly
5% of the global CVD mortality and disease burden occurring in
eveloping countries (2). That is mainly due to the absence of
ppropriate infrastructure for specialized diagnostic and treatment
ervices for CVDs.
It is estimated that by 2015, the number of deaths due to
oncommunicable diseases in Africa will exceed those due to
ommunicable diseases (3). The majority of these shifts will occur
n the emerging CVD pandemic. By year 2020, the CVD mortalitynd by 126% in women (3). Furthermore, by 2025, prevalence
ates for diabetes mellitus in developing countries will increase by
70%, from 84 million to 228 million, or more than 75% of the
lobal burden of diabetes (3). The crisis at hand presents a
ombination of moral, socioeconomic, and security challenges for
he global community.
This is why we believe that organizations such as the ACC can
lay a significant role in facilitating the development of local
nfrastructure and sustainable programs in developing economies.
his is the concept that underlies the mission of the Heart
nstitute of the Caribbean, where we have shown that with careful
lanning, smart design, and appropriate use of technology, sus-
ainable and affordable high-quality cardiovascular care anchored
n aggressive prevention and treatment strategies can be developed
n low-resource economies (4). We are now expanding our model
o countries in Africa such as Nigeria, Ghana, and Tanzania. We
ee and encourage a major role for the ACC in promoting such
odels of cardiovascular care in developing countries. The type of
are that is taken for granted in the U.S. and Europe can indeed be
vailable globally.
The ACC must also explore collaborations in developing
ountries that will foster dialogue with cardiovascular specialists
nd encourage appropriate capacity building and development of
ulticultural competencies (5).
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eply
s an organization based in the U.S., the American College of
ardiology recognizes that it has as much to learn as it has to teach
rom our engagements with partners outside the U.S. The goals
nd examples outlined in the letter from Dr. Madu and colleagues
oncerning my recent report (1) are shared ones, and we must work
ollaboratively in order to reach them.
The College’s recent international strategy has been developed
rst and foremost to be collaborative and not prescriptive with
ther international societies and with our international members,
nd second, to work with willing partners to better understand the
eeds that cardiovascular specialists have on a local level to develop
rograms and products that help mitigate those challenges and
mprove the care of all patients with cardiovascular disease. For this
eason, the College has implemented a new international gover-
ance structure aimed at improving international representation
nd exchange. Our primary goals are to provide better value of
embership to our international members, to foster collaboration
round global issues, to improve the care of patients with cardio-
ascular disease, and last, to provide educational and quality
mprovement resources to those wishing to collaborate. We
trongly believe that our strategy of collaboration in both resource-
ich as well as resource-limited settings will help us to achieve our
hared vision of improving quality patient-centered cardiovascular
are globally. I urge you and other international members to
ecome involved in the International Council—which now pro-
ides forums for you to advance initiatives and sustainable struc-
ures to improve world cardiovascular health.
. Douglas Weaver, MD*
Henry Ford Heart and Vascular Institute
799 West Grand Boulevard K-14
etroit, Michigan 48202-2608
-mail: wweaver1@hfhs.orgdoi:10.1016/j.jacc.2009.05.042 rEFERENCE
. Weaver DW. President’s page: the continuing importance of interna-
tional engagement. J Am Coll Cardiol 2008;51:2193–4.
ole of International
edical Graduates in the
merican College of Cardiology
read with much interest the recent commentary by Dr. W.
ouglas Weaver (1), President of the American College of
ardiology (ACC), in which he addressed the challenges that
nternational medical graduates (IMGs) face when they enter
ellowship programs or clinical practice in the U.S. and proposed
deas to get them more involved and integrated in the functions of
he ACC. Because I am an IMG myself, it was rewarding to see
hat the ACC at its highest leadership level is genuinely interested
n the welfare of IMGs, who certainly go through difficult times to
et into a cardiology fellowship program in the U.S. in the first
lace.
Although most IMGs who complete their cardiovascular train-
ng end up staying in the U.S. in private practice or academic
ositions, a substantial portion do actually go to their countries
mainly developing countries) to start their careers there. Those
lso tend to disconnect from the ACC and, other than attending
he annual ACC or American Heart Association scientific ses-
ions, they are not so much involved in the functions of the college.
any of those IMGs have received rigorous research training in
he U.S. in addition to their clinical training, and unfortunately
heir research productivity significantly decreases once they leave
he U.S. (2). Limited funding, the absence of senior supporting
entors, and the lack of dedicated time all combine to significantly
urtail the research potential of IMGs returning to their develop-
ng countries. How can the ACC support and enhance the
cademic careers of IMGs in their home countries?
First, encourage them to continue their research and to publish
t. There is a feeling, which may be difficult to prove, that there is
certain bias in U.S. and European journals against research
erformed in developing countries. Most of the research conducted
n these countries is clinical rather than basic and although it might
ot be directly relevant to the U.S. health care system, it remains
elevant to “global cardiovascular health.” The ACC could help
MGs by having its journals more “open” to their research or
erhaps having a journal dedicated to cardiovascular health in
eveloping countries just like it has journals dedicated to imaging
r interventions.
Second, help them create a network with leading pharmaceu-
ical companies conducting clinical trials. Most of those companies
iew developing countries primarily as markets for their products,
nd although some of them are beginning to conduct clinical trials
n these countries, their attempts have not been always successful
ecause of the lack of supporting infrastructure and improper
election of sites and investigators. Proper networking among the
CC, pharmaceutical companies, and investigators with solidesearch background can ensure the success of the clinical trials
